Narcotic strength scale. Opioid Potency Scale: Understanding Narcotic Strength and Equivalence

06.08.202308.07.2023 by alexxlab

How does opioid potency compare across different medications. What factors influence the relative strength of various narcotics. Which opioids are considered strongest and weakest on the potency scale.

Содержание

The Complexities of Comparing Opioid Potency

Creating a definitive list of opioids from strongest to weakest is not as straightforward as it may seem. While potency comparisons can be made, several factors complicate direct strength rankings:

Differences in mechanism of action between opioids
Variations in potency based on route of administration
Presence or absence of dose ceilings
Individual patient factors affecting drug response

Understanding these nuances is crucial for healthcare providers and patients alike to ensure safe and effective pain management. Let’s explore the key considerations in evaluating opioid strength.

Morphine as the Standard Reference for Opioid Potency

Morphine serves as the benchmark against which other opioids are typically compared. The CDC and other health organizations often use morphine milligram equivalents (MME) to standardize potency comparisons. This allows for a relative assessment of opioid strength, though it doesn’t account for all pharmacological differences between drugs.

Why is morphine used as the standard? Its long history of use, well-understood pharmacology, and lack of a dose ceiling make it an ideal reference point. However, it’s important to note that equivalent doses of different opioids may not produce identical effects in all patients.

Morphine Milligram Equivalents (MME) Explained

MME represents the amount of morphine that would provide equivalent analgesic effect to a given dose of another opioid. For example, if Drug A has an MME of 2, it means 1 mg of Drug A is equivalent in potency to 2 mg of morphine. This allows for standardized comparisons across different opioid medications.

Factors Influencing Opioid Potency and Effectiveness

Several key factors can impact the relative strength and effectiveness of opioid medications:

Route of administration (oral, intravenous, transdermal, etc.)
Formulation (immediate-release vs. extended-release)
Individual patient metabolism and tolerance
Presence of other medical conditions
Drug interactions
Genetic factors affecting opioid receptor sensitivity

These variables mean that a simple ranking of opioids by potency may not accurately reflect real-world clinical outcomes. Healthcare providers must consider these factors when selecting and dosing opioid medications.

Comparing Potency: The WHO Opioid Equivalence Chart

The World Health Organization (WHO) provides a valuable resource for comparing opioid potency in their “Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents.” This chart offers approximate potency ratios relative to morphine for various opioids.

Key Points from the WHO Opioid Equivalence Chart

Potency ratios are given for oral and immediate-release formulations unless otherwise stated
The chart allows for conversion between morphine and other opioids
Caution is advised when using these ratios, as individual patient response may vary
Some opioids, like methadone, have complex pharmacokinetics that complicate direct comparisons

It’s crucial to note that while this chart provides valuable guidance, it should not be used as a sole determinant for opioid selection or dosing. Clinical judgment and patient-specific factors must always be considered.

Strongest Opioids: Potent Narcotics at the Top of the Scale

While potency can vary based on factors previously discussed, certain opioids are generally recognized as being among the strongest available:

Carfentanil

Carfentanil is an extremely potent synthetic opioid, estimated to be 10,000 times more potent than morphine. It is not approved for human use and is primarily used in veterinary medicine for large animals. The extreme potency of carfentanil makes it incredibly dangerous, with a high risk of overdose even in minute quantities.

Fentanyl

Fentanyl is a synthetic opioid approximately 50-100 times more potent than morphine. It is used medically for severe pain management, often in patch form for chronic pain or intravenously in surgical settings. The high potency of fentanyl has also led to its illicit manufacture and distribution, contributing significantly to the opioid crisis.

Sufentanil

Sufentanil is another highly potent synthetic opioid, roughly 5-10 times more potent than fentanyl and 500-1000 times more potent than morphine. Its primary medical use is in anesthesia and for management of severe acute pain in hospital settings.

These ultra-potent opioids require extremely careful handling and administration due to their strength and narrow therapeutic window.

Moderate Strength Opioids: Balancing Potency and Safety

In the middle range of the opioid potency scale, we find medications that offer significant pain relief while generally having a more manageable safety profile compared to the strongest opioids:

Hydromorphone (Dilaudid)

Hydromorphone is approximately 4-8 times more potent than morphine. It is commonly used for moderate to severe pain management in both hospital and outpatient settings. Its relatively short half-life can be advantageous for titration but may require more frequent dosing for sustained pain relief.

Oxycodone

Oxycodone is roughly 1.5 times more potent than morphine when administered orally. It is widely prescribed for moderate to severe pain and is available in both immediate-release and extended-release formulations. The popularity of oxycodone has unfortunately contributed to its misuse and abuse potential.

Methadone

Methadone presents a unique case in opioid comparisons. While a single 5 mg dose may be equivalent to only 7.5 mg of morphine, its long half-life and complex receptor interactions can lead to much higher relative potency with regular administration. This makes methadone challenging to compare directly and necessitates careful management by experienced clinicians.

These moderate-strength opioids offer effective pain relief options when stronger medications are not necessary or advisable. However, they still carry risks of dependence and side effects, requiring careful prescribing and monitoring.

Weaker Opioids: Lower Potency Options for Pain Management

At the lower end of the opioid potency scale, we find medications that offer pain relief with generally lower risks of severe side effects or overdose. These opioids are often used as first-line treatments for moderate pain or in patients who cannot tolerate stronger options:

Codeine

Codeine is considered a weak opioid, with potency about 1/10th that of morphine. It is often combined with non-opioid analgesics like acetaminophen for enhanced pain relief. Codeine’s effectiveness can vary significantly between individuals due to genetic differences in metabolism.

Tramadol

Tramadol is a unique opioid with dual mechanisms of action. It has opioid effects and also inhibits the reuptake of serotonin and norepinephrine. Its potency relative to morphine is variable, ranging from about 1/10th to 1/5th depending on the individual and dosage. Tramadol is often used for moderate pain and may have a lower risk of respiratory depression compared to traditional opioids.

Hydrocodone

While stronger than codeine, hydrocodone is generally considered less potent than morphine when taken orally. It is commonly prescribed in combination with acetaminophen for management of moderate to moderately severe pain. The potency of hydrocodone relative to morphine can vary based on formulation and individual factors.

These lower-potency opioids can be valuable tools in pain management, offering a step between non-opioid analgesics and stronger narcotic options. However, they still carry risks of dependence and side effects, particularly when used long-term or in high doses.

The Role of Non-Opioid Analgesics in Pain Management

While discussing opioid potency, it’s crucial to recognize the importance of non-opioid pain management strategies. These alternatives can be effective for many types of pain and may reduce the need for opioid medications:

Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen
Acetaminophen (paracetamol)
Gabapentinoids for neuropathic pain
Topical analgesics
Non-pharmacological approaches like physical therapy, acupuncture, and cognitive behavioral therapy

Integrating these non-opioid options into pain management strategies can help minimize opioid use and associated risks. A multimodal approach to pain often provides the best outcomes for patients.

Combining Opioids with Non-Opioid Analgesics

In many cases, combining lower doses of opioids with non-opioid pain relievers can provide effective pain management while reducing opioid-related risks. This approach, known as multimodal analgesia, takes advantage of different pain-relief mechanisms to optimize outcomes.

For example, combining a low-dose opioid with an NSAID can provide synergistic pain relief, potentially allowing for lower opioid doses and reduced side effects. However, such combinations must be carefully managed to avoid adverse interactions and cumulative toxicity.

Safety Considerations in Opioid Use and Prescribing

Regardless of potency, all opioids carry risks of side effects, dependence, and potential for misuse. Key safety considerations include:

Proper patient screening and risk assessment before prescribing opioids
Starting with the lowest effective dose and titrating carefully
Regular monitoring for side effects, efficacy, and signs of misuse
Educating patients on safe storage and disposal of opioid medications
Implementing opioid-sparing strategies when possible
Being aware of potential drug interactions, particularly with other central nervous system depressants

Healthcare providers must balance the need for effective pain management with the risks associated with opioid use. This often involves a comprehensive approach that may include non-opioid therapies, behavioral interventions, and careful opioid selection and dosing when necessary.

The Importance of Individualized Treatment Plans

While understanding opioid potency is crucial, it’s equally important to recognize that pain management should be tailored to each patient’s unique needs and circumstances. Factors to consider include:

The type and severity of pain
Patient’s medical history and comorbidities
Previous responses to pain treatments
Patient preferences and goals
Risk factors for opioid misuse or adverse effects

By taking a patient-centered approach, healthcare providers can develop treatment plans that optimize pain relief while minimizing risks associated with opioid use.

The Future of Pain Management: Beyond Traditional Opioids

As concerns about opioid-related risks continue to grow, researchers are exploring new approaches to pain management that may reduce reliance on traditional opioids:

Novel Opioid Formulations

Scientists are developing new opioid formulations designed to minimize abuse potential and side effects. These include:

Abuse-deterrent formulations that resist crushing or dissolving for illicit use
Biased agonists that selectively activate beneficial opioid receptor pathways while minimizing adverse effects
Peripherally-acting opioids that do not cross the blood-brain barrier, potentially reducing central nervous system side effects

Non-Opioid Pain Medications

Research into non-opioid pain relief mechanisms is ongoing, with promising developments in areas such as:

Nerve growth factor inhibitors for chronic pain conditions
Novel sodium channel blockers for neuropathic pain
Cannabinoid-based medications for various pain types

Advanced Non-Pharmacological Interventions

Technological advancements are expanding the possibilities for non-drug pain management:

Neuromodulation techniques like spinal cord stimulation and transcranial magnetic stimulation
Virtual reality therapy for pain distraction and management
Advanced physical therapy techniques and rehabilitation technologies

These emerging approaches hold promise for expanding pain management options beyond traditional opioids, potentially offering effective relief with reduced risks of addiction and side effects.

As our understanding of pain mechanisms and opioid pharmacology continues to evolve, so too will our approaches to pain management. The goal remains to provide effective pain relief while minimizing risks and improving overall patient outcomes. While opioids will likely continue to play a role in pain management, particularly for severe acute pain and end-of-life care, the future may see a more diverse and personalized approach to pain treatment.

Table A6.2, Approximate potency of opioids relative to morphine; PO and immediate-release formulations unless stated otherwisea – WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: World Health Organization; 2018.

WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents.

Show details

Contents

Search term

Table A6.2Approximate potency of opioids relative to morphine; PO and immediate-release formulations unless stated otherwise

: Source: Adapted with permission from Twycross et al. 2017:371 (Table 4) (3).
a: Multiply dose of opioid in the first column by relative potency in the second column to determine the equivalent dose of morphine sulfate/hydrochloride; conversely, divide morphine dose by the relative potency to determine the equivalent dose of another opioid.
b: Dependent in part on severity of pain and on dose; often longer-lasting in very elderly and those with renal impairment.
c: The numbers in parenthesis are the manufacturers’ preferred relative potencies.
d: A single 5 mg dose of methadone is equivalent to morphine 7.5 mg, but a variable long plasma half-life and broad-spectrum receptor affinity result in a much higher-than-expected relative potency when administered regularly – sometimes much higher than the range given above. Therefore, guidance from a specialist is recommended for conversions to regularly administered methadone.

From: ANNEX 6, Pharmacological Profiles and Opioid Conversion Tables

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Contents

Cite this Page
PDF version of this title (1.2M)
Disable Glossary Links

Other titles in this collection

WHO Guidelines Approved by the Guidelines Review Committee

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Discover the List of Opioids From Strongest to Weakest to Avoid Overdose Updated 2023

Creating a list of opioids from strongest to weakest is not as straightforward as simply listing them by potency or by an analgesic effect. A report released by the CDC (1) listed various narcotic pain medications by strength as they compared to morphine. Yet the list doesn’t determine whether the medication also has a similar mechanism of action. Some of the strongest types of pain medication in a hospital may have a similar potency to morphine, but they may also be formulated with a dose ceiling, while morphine does not, rendering them less potent overall.

The actual potency of some narcotic pain medications and prescription opioids, or pain relievers by strength, may also vary, depending on the route of administration. Essentially, the list of opioids strongest to weakest is determined by factoring in that a smaller dose of certain painkiller medications may be required to achieve the same pain-relief response to treat severe pain as can be reached with morphine.

Fentanyl is common among drug abusers and is one of the strongest opioids on the market and is the strongest pain medication in hospital settings. This drug can lead to abuse and addiction. The opioid painkiller medication has a rapid onset and short duration of action. It’s occasionally used as a part of the anesthesia process to help prevent pain following surgery but it is also used to treat severe pain. Depending on the method of administration, it’s estimated that fentanyl can be up to 100 times more potent than morphine and is classified as one of the strongest opioids.

Heroin is created by combining the morphine alkaloid with acetic anhydride to create a more potent opioid analgesic drug. While heroin was once used in medical settings, it was made a Schedule I Substance under the Controlled Substances Act in 1924 and is now an illicit drug used primarily for recreational purposes. It’s estimated that heroin is approximately 2 to 4 times more potent than morphine. Heroin addiction is a contributing factor to the drug epidemic that the U.S. is facing and is leading to mass overdose deaths.

Tapentadol (Nucynta, Palexia SR): Technically, tapentadol could be classified as stronger than morphine, as clinical trials (3) indicate the medication provides superior analgesic effects than equivalent doses of oxycodone, but with significantly lower gastrointestinal side effects. However, as tapentadol has a dose ceiling, so it’s listed as a morphine-equivalent ahead in order of strength to morphine.

Hydrocodone is a semi-synthetic opiate analgesic created from the codeine alkaloid found within the opium poppy. Hydrocodone is commonly used to treat moderate to severe pain and is predominantly used within the United States, with 99% of the world’s volume of hydrocodone consumed in that country. Hydrocodone is also commonly available in a variety of formulations, including combinations with paracetamol (Vicodin), ibuprofen (Vicoprofen), or aspirin (Lortab).

Of the list of opioids strongest to weakest, the least potent opiate is still available from some pharmacies in the US and UK. The formulation is used primarily to control diarrhea or to ease withdrawal symptoms in babies born to opiate-addicted mothers. In the 1800s morphine was known as laudanum and was readily available from grocers and markets, but was soon restricted once its addictive qualities were known. Today, laudanum is sold as a ‘tincture of opium,’ which contains approximately 10% (100mg) powdered opium, or the equivalent of 1% (10mg) morphine per milliliter. The tincture is considered a single formulation, as it contains all of the alkaloids found within the opium poppy.